This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jun 16, 2026
•
3 min read
🧬 Intellia Therapeutics' (lonvoguran ziclumeran) achieves 89% attack reduction in Ph3 hereditary angioedema study, Germany drops variable drug discount plans after Boehringer Ingelheim and Eli Lilly withdraw investments, Recipharm channels multi-million-dollar U.S. manufacturing upgrade to meet surging domestic biologics demand
Jun 15, 2026
🧬 AstraZeneca's Truqap (capivasertib) wins FDA approval for PTEN-deficient metastatic prostate cancer following Ph3 data, Eli Lilly's Jaypirca (pirtobrutinib) combo cuts progression risk by nearly half in Ph3 chronic lymphocytic leukemia study, Johnson & Johnson's Talvey (talquetamab) plus Darzalex Faspro (daratumumab) combo demonstrates Ph3 superiority in relapsed or refractory multiple myeloma
Jun 12, 2026
🧬 Novartis' (delpacibart braxlosiran) meets primary endpoints in Ph1/2 trial for facioscapulohumeral muscular dystrophy, Amgen enlists Duke Clinical Research Institute to defend Tavneos against FDA withdrawal push, Enliven Therapeutics' ELVN-001 shows improved Ph1 efficacy in heavily pretreated chronic myeloid leukemia patients ahead of Ph3
Jun 11, 2026
🧬 Takeda's (zasocitinib) beats Bristol Myers Squibb's Sotyktu in Ph3 head-to-head trial for plaque psoriasis, Kardigan plans $320M IPO to advance four cardiovascular pipeline assets, Pfizer CEO Bourla warns Germany's healthcare reform plan threatens future investments in the country
Jun 10, 2026
🧬 Parabilis Medicines raises $670M IPO, largest-ever biotech debut for cancer drug developer, Novartis, Orionis Biosciences expand molecular glue collaboration with $40M upfront, up to $1.4B milestones, SonoThera raises $125M Series B, advancing bubble-based genetic medicine delivery platform
Jun 9, 2026
🧬 GSK to acquire Nuvalent Bio for $10.6B, securing precision oncology pipeline in industry's second-largest deal, Parabilis Medicines plans up to $636.8M IPO, advancing rare tumor candidate zolucatetide, Gilead, Merck & Co.'s (islatravir/lenacapavir) meets primary endpoint in Ph3 trials for human immunodeficiency virus type 1
Jun 8, 2026
4 min read
🧬 Eli Lilly's retatrutide achieves 30.3% weight reduction at 104 weeks in Ph3 trial for obesity, Johnson & Johnson acquires Firefly Bio for $1B upfront to access DAC platform targeting KRAS-driven tumors, Hikma Pharmaceuticals invests $267M to expand two Ohio manufacturing sites, adding 350 jobs
Jun 5, 2026
🧬 Pfizer partners with Chai Discovery on AI-driven drug discovery using custom and Chai-3 models, Hikma Pharmaceuticals wins unanimous Supreme Court ruling in landmark skinny labels patent case against Amarin, Otsuka Pharmaceuticals' Voyxact (sibeprenlimab) Ph3 data show kidney function stabilization in immunoglobulin A nephropathy
Jun 4, 2026
🧬 Innovent Biologics' (arcotatug tavatecan) hits Ph3 win in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma, Alnylam Pharmaceuticals, Inceptive Nucleics partner on AI-driven siRNA drug discovery, $30M upfront, up to $2B total, Parabilis plans up to $476M IPO, advancing peptide drug zolucatetide for desmoid tumors
Jun 3, 2026
🧬 Legend Biotech's (LB2501) achieves 100% response rate in Ph1 non-Hodgkin lymphoma in vivo CAR T study, NewLimit raises $435M Series C, advancing epigenetic reprogramming medicine toward human trials, Eli Lilly, Ascidian Therapeutics partner on RNA exon editing for kidney diseases, up to $1.9B
Jun 2, 2026
🧬 Moderna, Merck & Co.'s (intismeran autogene) plus Keytruda shows 49% recurrence risk reduction in Ph2b high-risk melanoma, Bristol Myers Squibb's (izalontamab brengitecan) Ph3 trial shows 40% reduced death risk in triple-negative breast cancer, Rallybio merges with Avenzo Therapeutics in reverse merger, backed by $215M private placement
Jun 1, 2026
🧬 Eli Lilly's Kelonia Therapeutics' (KLN-1010) shows 100% response rate in Ph1 relapsed or refractory multiple myeloma trial, Revolution Medicines' daraxonrasib nearly doubles survival in Ph3 metastatic pancreatic cancer with KRAS mutation, Gilead's TUB-040 (NaPi2b-targeting ADC) shows 61% tumor response in Ph1 platinum-resistant ovarian cancer trial
May 30, 2026
8 min read
Selling to Scientists & Technical Industries
May 29, 2026
🧬 Pfizer, Innovent Biologics strike $10B cancer deal covering 12 ADC and multispecific antibody programs, $650M upfront, AstraZeneca's Imfinzi (durvalumab) wins FDA approval for BCG-naïve high-risk non-muscle-invasive bladder cancer after Ph3 win, Replimune resubmits RP1 melanoma BLA for third time following major FDA leadership shakeup
May 28, 2026
🧬 GSK, Ionis Pharmaceuticals' (bepirovirsen) achieves Ph3 functional cure in nearly 20% of chronic hepatitis B patients, AbbVie's Decnupaz wins FDA approval for blastic plasmacytoid dendritic cell neoplasm, targeting CD123 in Ph1/2, Secretome Therapeutics raises $30M Series A to advance cardiac cell therapies pipeline
May 27, 2026
🧬 Outlook Therapeutics' Lytenava (bevacizumab) gains FDA appeal win for wet age-related macular degeneration, AstraZeneca's (camizestrant) FDA review delayed after advisory committee rejects Ph3 data for HR-positive breast cancer, Astellas unveils five-year growth strategy to offset Xtandi patent expiry through pipeline acquisitions
May 26, 2026
🧬 Eli Lilly to acquire Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8B to build infectious disease pipeline
May 22, 2026
🧬 Eli Lilly's (retatrutide) Ph3 TRIUMPH-1 delivers bariatric surgery–level weight loss in obesity patients, Research Alliance III raises $75M SPAC IPO, targeting China-based biotech merger, Merck & Co., Kelun-Biotech's (sacituzumab tirumotecan) plus Keytruda cuts progression risk 65% in Ph3 non-small cell lung cancer
May 21, 2026
🧬 Parabilis Medicines files for IPO after raising $800M, targeting "undruggable" oncology proteins, Eli Lilly acquires Engage Bio for up to $202M to expand nonviral DNA delivery platform, Bristol Myers Squibb, Anthropic partner to deploy Claude AI across drug development operations
May 20, 2026
🧬 UCB's Bimzelx (bimekizumab) outperforms Skyrizi in Ph3 head-to-head trial for psoriatic arthritis, Incyte, Edison Scientific partner to deploy Kosmos AI across drug discovery and R&D workflows, Mentari Therapeutics goes public via reverse merger with InMed Pharmaceuticals, raising $290M for migraine pipeline
May 19, 2026
🧬 Bristol Myers Squibb weighs $1B Houston manufacturing plant that could employ 500 people, Merck & Co.'s (sacituzumab tirumotecan) hits Ph3 mark in endometrial cancer, beating chemotherapy in survival outcomes, Full-Life Technologies raises $150M Series D, advancing radiotherapeutics pipeline and Belgium manufacturing
May 18, 2026
🧬 Eisai projects $905M in Leqembi revenues for fiscal 2026, driven by subcutaneous auto-injector launch, Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) gains FDA approval for two HER2-positive breast cancer indications following Ph3 data, FDA's CDER, CBER acting directors and chief of staff ousted following Commissioner Makary's departure
May 14, 2026
🧬 BeOne Medicines' Beqalzi (sonrotoclax) receives FDA accelerated approval for relapsed or refractory mantle cell lymphoma as first BCL-2 inhibitor, Novo Nordisk's oral semaglutide delivers up to 21.6% weight loss in Ph3 obesity trial, Vetter breaks ground on new Saarlouis production site, investing €500M ($586.75M) to create up to 2,000 jobs
May 13, 2026
🧬 Isomorphic Labs raises $2.1B Series B to develop AI drug design engine, accelerate pipeline, FDA Commissioner Marty Makary resigns after turbulent tenure marked by White House tensions, Bristol Myers Squibb, Hengrui Pharma build 13-asset oncology and immune disease pipeline in $15.2B deal
May 12, 2026
🧬 Inhibrx Biosciences' INBRX-106 plus Keytruda (pembrolizumab) doubles response rate in Ph2 head and neck squamous cell carcinoma trial, Daiichi Sankyo targets $14.6B oncology sales by 2030, aiming for global top-five cancer company status, Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy STEM-PD, equity investment undisclosed
